Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q2 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $9.07 million versus the consensus estimate of $2.57 million.
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q2 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $9.07 million versus the consensus estimate of $2.57 million.